{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:42:14Z","timestamp":1787067734541,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T00:00:00Z","timestamp":1663718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00259-022-05967-7","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:03:23Z","timestamp":1663733003000},"page":"302-313","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["High in-vivo stability in preclinical and first-in-human experiments with [18F]AlF-RESCA-MIRC213: a 18F-labeled nanobody as PET radiotracer for diagnosis of HER2-positive cancers"],"prefix":"10.1007","volume":"50","author":[{"given":"Xue","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2084-5193","authenticated-orcid":false,"given":"Zhi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,9,21]]},"reference":[{"issue":"1","key":"5967_CR1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12032-014-0391-z","volume":"32","author":"Y Cai","year":"2015","unstructured":"Cai Y, Wang J, Zhang L, et al. Expressions of fatty acid synthase and HER2 are correlated with poor prognosis of ovarian cancer. Med Oncol. 2015;32(1):391.","journal-title":"Med Oncol"},{"issue":"9","key":"5967_CR2","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s00432-010-0790-2","volume":"136","author":"B Schluter","year":"2010","unstructured":"Schluter B, Gerhards R, Strumberg D, et al. Combined detection of HER2\/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer. J Cancer Res Clin Oncol. 2010;136(9):1389\u2013400.","journal-title":"J Cancer Res Clin Oncol"},{"key":"5967_CR3","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1093\/annonc\/12.suppl_1.S15","volume":"12","author":"S M\u00e9nard","year":"2001","unstructured":"M\u00e9nard S, Casalini P, Campiglio M, et al. HER2 overexpression in various tumor types, focusing on its relationship to the development of invasive breast cancer. Ann Oncol. 2001;12:S15\u20139.","journal-title":"Ann Oncol"},{"key":"5967_CR4","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/annonc\/12.suppl_1.S81","volume":"12","author":"S Scholl","year":"2001","unstructured":"Scholl S, Beuzeboc P, Pouillart P. Targeting HER2 in other tumor types. Ann Oncol. 2001;12:S81\u20137.","journal-title":"Ann Oncol"},{"issue":"1","key":"5967_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1750-9378-1-1","volume":"1","author":"FM Buonaguro","year":"2006","unstructured":"Buonaguro FM, Lewis GK, Pelicci P. Introducing infectious agents and cancer. Infect Agent Cancer. 2006;1(1):1.","journal-title":"Infect Agent Cancer"},{"issue":"19","key":"5967_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1093\/jnci\/djp341","volume":"101","author":"K Hede","year":"2009","unstructured":"Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst. 2009;101(19):1306\u20137.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"5967_CR7","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1309\/AJCP9MKNLHQNK2ZX","volume":"137","author":"DM Minot","year":"2012","unstructured":"Minot DM, Voss J, Rademacher S, et al. Image analysis of HER2 immunohistochemical staining. Reproducibility and concordance with fluorescence in situ hybridization of a laboratory-validated scoring technique. Am J Clin Pathol. 2012;137(2):270\u20136.","journal-title":"Am J Clin Pathol."},{"issue":"5","key":"5967_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","volume":"93","author":"J Zidan","year":"2005","unstructured":"Zidan J, Dashkovsky I, Stayerman C, et al. Comparison of HER2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer. 2005;93(5):552\u20136.","journal-title":"Br J Cancer"},{"issue":"7","key":"5967_CR9","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1158\/1078-0432.CCR-10-1920","volume":"17","author":"A Fabi","year":"2011","unstructured":"Fabi A, Di Benedetto A, Metro G, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. J Clin Cancer Res. 2011;17(7):2055\u201364.","journal-title":"J Clin Cancer Res"},{"key":"5967_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fonc.2013.00129","volume":"3","author":"A Sapino","year":"2013","unstructured":"Sapino A, Goia M, Recupero D, et al. Current challenges for HER2 testing in diagnostic pathology: state of the art and controversial issues. Front Oncol. 2013;3:129.","journal-title":"Front Oncol"},{"issue":"5","key":"5967_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.breast.2014.08.009","volume":"23","author":"F Cardoso","year":"2014","unstructured":"Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014;23(5):489\u201392.","journal-title":"Breast"},{"issue":"2","key":"5967_CR12","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1309\/99AE032R9FM8WND1","volume":"129","author":"DG Hicks","year":"2008","unstructured":"Hicks DG, Kulkarni S. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol. 2008;129(2):263\u201373.","journal-title":"Am J Clin Pathol"},{"issue":"28","key":"5967_CR13","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.2174\/138161208786404290","volume":"14","author":"V Tolmachev","year":"2008","unstructured":"Tolmachev V. Imaging of HER2 overexpression in tumors for guiding therapy. Curr Pharm Des. 2008;14(28):2999\u20133019.","journal-title":"Curr Pharm Des"},{"issue":"9","key":"5967_CR14","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrc882","volume":"2","author":"SS Gambhir","year":"2002","unstructured":"Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2(9):683\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"5967_CR15","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jfluchem.2006.09.015","volume":"127","author":"D Lebars","year":"2006","unstructured":"Lebars D. Fluorine-18 and medical imaging: radiopharmaceuticals for positron emission tomography. J Fluorine Chem. 2006;127(11):1488\u201393.","journal-title":"J Fluorine Chem"},{"key":"5967_CR16","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apradiso.2012.06.034","volume":"76","author":"A Sanchez-Crespo","year":"2013","unstructured":"Sanchez-Crespo A. Comparison of gallium-68 and fluorine-18 imaging characteristics in positron emission tomography. Appl Radia Isot. 2013;76:55\u201362.","journal-title":"Appl Radia Isot"},{"issue":"1","key":"5967_CR17","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.apradiso.2011.08.013","volume":"70","author":"WJ McBride","year":"2012","unstructured":"McBride WJ, D\u2019Souza CA, Sharkey RM, et al. The radiolabeling of proteins by the [18F]AlF method. Appl Radiat Isot. 2012;70(1):200\u20134.","journal-title":"Appl Radiat Isot"},{"issue":"6","key":"5967_CR18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2967\/jnumed.108.060418","volume":"50","author":"WJ McBride","year":"2009","unstructured":"McBride WJ, Sharkey RM, Karacay H, et al. A novel method of 18F radiolabeling for PET. J Nucl Med. 2009;50(6):99\u2013108.","journal-title":"J Nucl Med"},{"issue":"5","key":"5967_CR19","doi-asserted-by":"publisher","first-page":"691","DOI":"10.2967\/jnumed.112.113563","volume":"54","author":"W Wan","year":"2013","unstructured":"Wan W, Guo N, Pan D, et al. First experience of 18F-alfatide in lung cancer patients using a new lyophilized kit for rapid radiofluorination. J Nucl Med. 2013;54(5):691\u20138.","journal-title":"J Nucl Med"},{"issue":"3","key":"5967_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1021\/acs.bioconjchem.6b00012","volume":"27","author":"F Cleeren","year":"2016","unstructured":"Cleeren F, Lecina J, Billaud EM, et al. New chelators for low temperature Al18F-labeling of biomolecules. Bioconjugate Chem. 2016;27(3):790\u20138.","journal-title":"Bioconjugate Chem"},{"key":"5967_CR21","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.7150\/thno.20094","volume":"7","author":"F Cleeren","year":"2017","unstructured":"Cleeren F, Lecina J, Ahamed M, et al. Al18F-labeling of heat-sensitive biomolecules for positron emission tomography imaging. Theranostics. 2017;7:2924\u201339.","journal-title":"Theranostics"},{"issue":"5","key":"5967_CR22","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1007\/s11307-010-0428-4","volume":"13","author":"LO Gainkam","year":"2011","unstructured":"Gainkam LO, Keyaerts M, Caveliers V, et al. Correlation between epidermal growth factor receptor-specific nanobody uptake and tumor burden: a tool for noninvasive monitoring of tumor response to therapy. Mol Imaging Biol. 2011;13(5):940\u20138.","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"5967_CR23","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.copbio.2011.06.009","volume":"22","author":"I Vaneycken","year":"2011","unstructured":"Vaneycken I, D\u2019Huyvetter M, Hernot S, et al. Immuno-imaging using nanobodies. Curr Opin Biotechnol. 2011;22(6):877\u201381.","journal-title":"Curr Opin Biotechnol."},{"issue":"7","key":"5967_CR24","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1021\/acs.bioconjchem.2c00209","volume":"33","author":"B Hu","year":"2022","unstructured":"Hu B, Liu T, Li L, et al. IgG-Binding nanobody capable of prolonging nanobody-based radiotracer plasma half-life and enhancing the efficacy of tumor-targeted radionuclide therapy. Bioconjug Chem. 2022;33(7):1328\u201339.","journal-title":"Bioconjug Chem"},{"issue":"12","key":"5967_CR25","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.7150\/thno.74154","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Liu T, Shi L, et al. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking. Theranostics. 2022;12(12):5551\u201363.","journal-title":"Theranostics"},{"key":"5967_CR26","first-page":"157","volume-title":"Encyclopedia of Radiation Oncology","author":"TW Speer","year":"2013","unstructured":"Speer TW. Dissociation constant (Kd). In: Brady LW, Yaeger TE, editors. Encyclopedia of Radiation Oncology. Springer, Berlin: Heidelberg; 2013. p. 157\u20138."},{"issue":"20","key":"5967_CR27","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in Breast Cancer: American society of clinical oncology\/college of American pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36(20):2105\u201322.","journal-title":"J Clin Oncol"},{"issue":"4","key":"5967_CR28","doi-asserted-by":"publisher","first-page":"e0123401","DOI":"10.1371\/journal.pone.0123401","volume":"10","author":"Q Chen","year":"2015","unstructured":"Chen Q, Ma Q, Chen M, et al. An exploratory study on 99mTc-RGD-BBN peptide scint-imammography in the assessment of breast malignant lesions compared to 99mTc3P4-RGD2. PLoS One. 2015;10(4):e0123401.","journal-title":"PLoS One"},{"issue":"9","key":"5967_CR29","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2967\/jnumed.119.238782","volume":"61","author":"EL van der Veen","year":"2020","unstructured":"van der Veen EL, Suurs FV, Cleeren F, et al. Development and evaluation of Interleukin-2-derived radiotracers for PET imaging of T cells in mice. J Nucl Med. 2020;61(9):1355\u201360.","journal-title":"J Nucl Med"},{"issue":"9","key":"5967_CR30","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.2967\/jnumed.118.221671","volume":"60","author":"T Liu","year":"2019","unstructured":"Liu T, Liu C, Xu X, et al. Preclinical evaluation and pilot clinical study of Al18F-PSMA-BCH for prostate cancer PET imaging. J Nucl Med. 2019;60(9):1284\u201392.","journal-title":"J Nucl Med"},{"issue":"10","key":"5967_CR31","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00259-021-05249-8","volume":"48","author":"Q Xie","year":"2021","unstructured":"Xie Q, Liu T, Ding J, et al. Synthesis, preclinical evaluation, and a pilot clinical imaging study of [18F]AlF-NOTA-JR11 for neuroendocrine neoplasms compared with [68Ga]Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2021;48(10):3129\u201340.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"5967_CR32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.7150\/thno.8006","volume":"4","author":"R Chakravarty","year":"2014","unstructured":"Chakravarty R, Goel S, Cai W. Nanobody: the \u201cmagic bullet\u201d for molecular imaging. Theranostics. 2014;4(4):386\u201398.","journal-title":"Theranostics"},{"issue":"4","key":"5967_CR33","doi-asserted-by":"publisher","first-page":"650","DOI":"10.2967\/jnumed.113.127100","volume":"55","author":"M Pruszynski","year":"2014","unstructured":"Pruszynski M, Koumarianou E, Vaidyanathan G, et al. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. J Nucl Med. 2014;55(4):650\u20136.","journal-title":"J Nucl Med"},{"issue":"7","key":"5967_CR34","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1096\/fj.10-180331","volume":"25","author":"I Vaneycken","year":"2011","unstructured":"Vaneycken I, Devoogdt N, Van Gassen N, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011;25(7):2433\u201346.","journal-title":"FASEB J"},{"issue":"2","key":"5967_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/cmmi.491","volume":"7","author":"M D'Huyvetter","year":"2012","unstructured":"D\u2019Huyvetter M, Aerts A, Xavier C, et al. Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: evaluation of different bifunctional chelators. Contrast Media Mol Imaging. 2012;7(2):254\u201364.","journal-title":"Contrast Media Mol Imaging"},{"key":"5967_CR36","doi-asserted-by":"crossref","unstructured":"Xavier C, Vaneycken I, D'huyvetter M, et al. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 nanobodies for iPET imaging of HER2 receptor expression in cancer. J Nucl Med. 2013;54(5):776\u201384.","DOI":"10.2967\/jnumed.112.111021"},{"issue":"7","key":"5967_CR37","doi-asserted-by":"publisher","first-page":"708","DOI":"10.7150\/thno.8156","volume":"4","author":"M D'Huyvetter","year":"2014","unstructured":"D\u2019Huyvetter M, Vincke C, Xavier C, et al. Targeted radionuclide therapy with A 177Lu-labeled anti-HER2 nanobody. Theranostics. 2014;4(7):708\u201320.","journal-title":"Theranostics"},{"issue":"1","key":"5967_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2967\/jnumed.115.162024","volume":"57","author":"M Keyaerts","year":"2016","unstructured":"Keyaerts M, Xavier C, Heemskerk J, et al. Phase I study of 68Ga-HER2-nanobody for PET\/CT assessment of HER2 expression in breast carcinoma. J Nucl Med. 2016;57(1):27\u201333.","journal-title":"J Nucl Med"},{"issue":"4","key":"5967_CR39","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.nucmedbio.2016.01.002","volume":"43","author":"C Xavier","year":"2016","unstructured":"Xavier C, Blykers A, Vaneycken I, et al. 18F-nanobody for PET imaging of HER2 overexpressing tumors. Nucl Med Biol. 2016;43(4):247\u201352.","journal-title":"Nucl Med Biol"},{"issue":"21","key":"5967_CR40","doi-asserted-by":"publisher","first-page":"6616","DOI":"10.1158\/1078-0432.CCR-17-0310","volume":"23","author":"M D'Huyvetter","year":"2017","unstructured":"D\u2019Huyvetter M, De Vos J, Xavier C, et al. 131I-labeled Anti-HER2 Camelid sdAb as a theranostic tool in cancer treatment. Clin Cancer Res. 2017;23(21):6616\u201328.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"5967_CR41","doi-asserted-by":"publisher","first-page":"3524","DOI":"10.1021\/acs.molpharmaceut.9b00354","volume":"16","author":"Y Dekempeneer","year":"2019","unstructured":"Dekempeneer Y, B\u00e4ck T, Aneheim E, et al. Labeling of anti-HER2 nanobodies with astatine-211: optimization and the effect of different coupling reagents on their in vivo behavior. Mol Pharmaceutics. 2019;16(8):3524\u201333.","journal-title":"Mol Pharmaceutics"},{"issue":"21","key":"5967_CR42","doi-asserted-by":"publisher","first-page":"6482","DOI":"10.3390\/molecules26216482","volume":"26","author":"S Ge","year":"2021","unstructured":"Ge S, Li J, Yu Y, et al. Review: radionuclide molecular imaging targeting HER2 in breast cancer with a focus on molecular probes into clinical trials and small peptides. Molecules. 2021;26(21):6482.","journal-title":"Molecules"},{"issue":"5","key":"5967_CR43","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1007\/s00259-020-05094-1","volume":"48","author":"B Altunay","year":"2021","unstructured":"Altunay B, Morgenroth A, Beheshti M, et al. HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging. Eur J Nucl Med Mol Imaging. 2021;48(5):1371\u201389.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"5967_CR44","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.2967\/jnumed.118.224170","volume":"60","author":"Y Xing","year":"2019","unstructured":"Xing Y, Chand G, Liu C, et al. Early phase I study of a 99mTc-labeled anti\u2013programmed death ligand-1 (PD-L1) single-domain antibody in SPECT\/CT assessment of PD-L1 expression in non\u2013small cell lung cancer. J Nucl Med. 2019;60(9):1213\u201320.","journal-title":"J Nucl Med"},{"key":"5967_CR45","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.2967\/jnumed.120.255679","volume":"62","author":"M D'Huyvetter","year":"2021","unstructured":"D\u2019Huyvetter M, Vos JD, Caveliers V, et al. Phase I trial of 131I-GMIB-Anti-HER2-VHH1, a new promising candidate for HER2-targeted radionuclide therapy in breast cancer patients. J Nucl Med. 2021;62:1097\u2013105.","journal-title":"J Nucl Med"},{"issue":"6","key":"5967_CR46","doi-asserted-by":"publisher","first-page":"967","DOI":"10.2967\/jnumed.115.171306","volume":"57","author":"G Vaidyanathan","year":"2016","unstructured":"Vaidyanathan G, McDougald D, Choi J, et al. Preclinical evaluation of 18F-labeled anti-HER2 nanobody conjugates for imaging HER2 ceceptor expression by immuno-PET. J Nucl Med. 2016;57(6):967\u201373.","journal-title":"J Nucl Med"},{"issue":"2","key":"5967_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1002\/cmmi.408","volume":"6","author":"LO Gainkam","year":"2011","unstructured":"Gainkam LO, Caveliers V, Devoogdt N, et al. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imaging. 2011;6(2):85\u201392.","journal-title":"Contrast Media Mol Imaging"},{"issue":"1","key":"5967_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2191-219X-3-36","volume":"3","author":"WJ McBride","year":"2013","unstructured":"McBride WJ, Sharkey RM, Goldenberg DM. Radiofluorination using aluminum-fluoride (Al18F). EJNMMI Res. 2013;3(1):36.","journal-title":"EJNMMI Res"},{"issue":"10","key":"5967_CR49","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.2967\/jnumed.113.120600","volume":"54","author":"M Sandstr\u00f6m","year":"2013","unstructured":"Sandstr\u00f6m M, Velikyan I, Garske-Roman U, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med. 2013;54(10):1755\u20139.","journal-title":"J Nucl Med"},{"issue":"6","key":"5967_CR50","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s00259-013-2386-y","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M, et al. Reply to Reske. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(6):971\u20132.","journal-title":"Eur J Nucl Med Mol Imaging."},{"issue":"5","key":"5967_CR51","doi-asserted-by":"publisher","first-page":"730","DOI":"10.2967\/jnumed.113.131243","volume":"55","author":"J S\u00f6rensen","year":"2014","unstructured":"S\u00f6rensen J, Sandberg D, Sandstrom M, et al. First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule. J Nucl Med. 2014;55(5):730\u20135.","journal-title":"J Nucl Med"},{"issue":"7","key":"5967_CR52","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1021\/acs.bioconjchem.1c00136","volume":"32","author":"M Chomet","year":"2021","unstructured":"Chomet M, van Dongen GAMS, Vugts DJ. State of the art in radiolabeling of antibodies with common and uncommon radiometals for preclinical and clinical immuno-PET. Bioconjug Chem. 2021;32(7):1315\u201330.","journal-title":"Bioconjug Chem"},{"issue":"1","key":"5967_CR53","first-page":"81","volume":"4","author":"JA Cohen","year":"1989","unstructured":"Cohen JA, Weiner DB, More KF, et al. Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract. Oncogene. 1989;4(1):81\u20138.","journal-title":"Oncogene"},{"issue":"34","key":"5967_CR54","doi-asserted-by":"publisher","first-page":"9732","DOI":"10.1039\/c1cc13151f","volume":"47","author":"D Shetty","year":"2011","unstructured":"Shetty D, Choi SY, Jeong JM, et al. Stable aluminium fluoride chelates with triazacyclononane derivatives proved by X-ray crystallography and 18F-labeling study. Chem Commun. 2011;47(34):9732\u20134.","journal-title":"Chem Commun"},{"issue":"8","key":"5967_CR55","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.3390\/molecules25081838","volume":"25","author":"J Bridoux","year":"2020","unstructured":"Bridoux J, Neyt S, Debie P, et al. Improved detection of molecular markers of atherosclerotic plaques using sub-millimeter PET imaging. Molecules. 2020;25(8):1838.","journal-title":"Molecules"},{"issue":"10","key":"5967_CR56","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1038\/s41596-018-0040-7","volume":"13","author":"F Cleeren","year":"2018","unstructured":"Cleeren F, Lecina J, Bridoux J, et al. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al18F-RESCA method. Nat Protoc. 2018;13(10):2330\u201347.","journal-title":"Nat Protoc"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-022-05967-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-022-05967-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:07:03Z","timestamp":1672891623000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-022-05967-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,21]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["5967"],"URL":"https:\/\/doi.org\/10.1007\/s00259-022-05967-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,21]]},"assertion":[{"value":"1 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by Ethics Committee of Beijing Cancer Hospital and Institute (no. 2021KT108). Informed consent was obtained from all individual participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from the 6 individual participants included in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}